IN VITRO AND IN VIVO EVALUATION OF POLY (CAPROLACTONE FUMARATE) NANOPARTICLES

Retraction Note :

Shokri N, Azizi E, Akbari Javar H, Fouladdel Sh, Khalaj A, Dinarvand R. In vitro and in vivo evaluation of poly (caprolactone fumarate) nanoparticles. International Journal of Pharmaceutical Sciences and Research. 2012; 3(9):3106-3115.  

It has come to the attention of the IJPSR Editors that there are substantial overlaps between the text of the above article and the following papers. It has been pointed out that the above study appeared to contain a high level of similarity with two articles by the same authors published as below:

Shokri N, Akbari Javar H, Fouladdel Sh, Khalaj A, Khoshayand M, Dinarvand R, Atyabi F, Nomani A, Azizi E. Preparation and evaluation of poly (caprolactone fumarate) nanoparticles containing doxorubicin HCI. Daru. 2011;19(1):12-22. PMID: 22615635.

and

Shokri N, Akbari Javar H, Fouladdel Sh, Khalaj A, Dinarvand R, Azizi E. Preparation and characterization of crosslinked and non-crosslinked polycaprolactone fumarate (PCLF) NPs as carriers for doxorubicin HCl. Afr J Pharm Pharmacol. 2011;5(7):797-805.

Following an internal investigation, it was established that the studies were conducted along broadly similar lines. Submitting multiple articles derived from the same data set with the overlap without cross-referencing is not legitimated. Moreover, there was a copyright infringement in some figures and formulas. In view of the extensive verbatim use of text from other sources, the IJPSR Editors retracted this article from the journal website.